Latest Articles
Aims Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve heart failure (HF) outcomes but their effects on acute myocardial infarction (AMI) remains poorly characterized. This study aimed to evaluate the one-year cardiovascular outcomes of SGLT2-Is among patients with AMI. Methods and ...
Aims Cardiovascular disease (CVD) and cancer represent significant global health challenges. An overlap between oncology and cardiology is compounded by cancer therapies, which are known to have cardiotoxic effects. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed for ...
Most read
Aims Cardiologists have only had rare exposure to haemophilia patients and patients with other congenital bleeding disorders during the last decades, as these patients had a reduced life expectancy and were partly protected against thrombosis due to the bleeding disorder. With the availability of effective and safe ...
Background People with lower extremity peripheral artery disease (PAD) suffer from a high burden of symptoms and significant functional impairment. There are few therapies that improve function and reduce symptoms in this population. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to improve glycaemic ...
Despite substantial advances in cardiovascular pharmacotherapy and devices in recent years, prevention and treatment of many cardiovascular diseases (CVDs) remain limited, thus reflecting the need for more effective and safer pharmacological strategies. In this review, we summarize the most relevant studies in ...
Conflict of interest: S.S. recieved speakers/consulting honoraria from AstraZeneca, Novartis, Berlin-Chemie, Daiichi Sankyo, Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, and Lilly. P.S. reports grants from Daiichi Sankyo and grants and personal fees from Boehringer Ingelheim and grants from AstraZeneca outside the ...
The clinically important link between LDL cholesterol (LDL - C) lowering and cardiovascular (CV) risk reduction is well-established and reflected in the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines for the management of dyslipidaemia. They recommend a stepwise approach to reaching LDL - C ...
Background Atherosclerotic cardiovascular disease (ASCVD) encompasses various phenotypes with elevated risks of major adverse cardiovascular events (MACEs). This study aimed to assess the comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium–glucose cotransporter-2 ...
Read comments on hot topics, key messages from conferences and events, informative features on cardiovascular pharmacology personalities, and notices from the Working Group on Cardiovascular Pharmacotherapy.
Read the latest PharmaPulse papers
Follow @EditorEHJCVP on X
Connect with Editor-in-Chief, Stefan Agewall, and stay up to date with the latest news and content from EHJ-CVP.
Join the conversation with #EHJPharmacotherapy
From the ESC
Discover European Heart Journal – Cardiovascular Pharmacotherapy’s top 20 most read articles published within the past 12 months.
Explore the collection
Discover the ESC Content Collections hub, now home to the latest content and collections from the ESC publications.
Read the latest collections
Visit the ESC Publications website to browse journals, books, guidelines, and online resources from the ESC. Stay up to date with the latest journal news.
Explore ESC Publications
